Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 23, 2015 12:53 AM ET

Pharmaceuticals

Company Overview of Cempra, Inc.

Company Overview

Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases in North America. Its lead product candidates include solithromycin (CEM-101), which is in Phase III clinical trials for the treatment of community acquired bacterial pneumonia, as well as for uncomplicated bacterial urethritis; and Taksta (CEM-102), an antibiotic that has completed Phase II clinical trials for refractory bone and joint infections. The company also produces novel macrolides for non-antibiotic uses, such as the treatment of chronic inflammatory diseases, endocrine diseases, and gastric motility disorders. It has colla...

6320 Quadrangle Drive

Suite 360

Chapel Hill, NC 27517

United States

Founded in 2005

55 Employees

Phone:

919-313-6601

Key Executives for Cempra, Inc.

Founder, Chief Executive Officer, President and Director
Age: 65
Total Annual Compensation: $475.0K
Chief Financial Officer and Executive Vice President
Age: 51
Total Annual Compensation: $325.0K
Chief Commercialization Officer and Executive Vice President
Age: 40
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2014.

Cempra, Inc. Key Developments

Cempra, Inc. Presents Results from Its Phase 3 Clinical Trial

Cempra, Inc. is presenting results from its Phase 3 clinical trial demonstrating the statistical non-inferiority of oral solithromycin versus oral moxifloxacin for the treatment of community acquired bacterial pneumonia (CABP). Oral solithromycin demonstrated statistical non-inferiority to oral moxifloxacin for the treatment of CABP and the solithromycin early clinical response (ECR) and short term follow-up (SFU) rates were numerically higher than moxifloxacin in the elderly, the patients at greater risk for CABP. Solithromycin was non-inferior to moxifloxacin on every pre-specified outcome measure in the study. The study consisted of a 1:1 randomization of 860 CABP patients to oral solithromycin for 5 days or oral moxifloxacin for 7 days, stratified by geographic region, by history of asthma and/or chronic obstructive pulmonary disease (COPD), and by PORT score (II vs. III/IV). PORT II severity pneumonia was capped in the study at 50%. The primary endpoint (for FDA) was non-inferiority (NI) in ECR rate at 72 hours in the intent-to-treat (ITT) population. The primary endpoint (for EMA) was NI in success rate at SFU visit, 5 to 10 days after end of therapy in the ITT and clinically-evaluable (CE) populations. Patients randomized to solithromycin received an 800 mg loading dose on day 1, 400 mg on days 2-5 and placebo on days 6 and 7. Patients in the moxifloxacin treatment arm received 400 mg on days 1-7. Oral solithromycin demonstrated statistical non-inferiority to oral moxifloxacin for the treatment of CABP with a treatment success rate in the ECR-ITT population of 78.2% for solithromycin and 77.9% for moxifloxacin. The 95% confidence interval for the treatment difference had lower and upper bounds of -5.5% and 6.1%, respectively. Notably, solithromycin ECR rates were numerically higher than moxifloxacin in patients over 75 years of age with a treatment success rate of 83.9% for solithromycin and 69.8% for moxifloxacin. The 95% confidence interval for the treatment success rate in this age group had lower and upper bounds of -2.1 and 30.2, respectively. In addition, oral solithromycin demonstrated NI for the SFU-ITT endpoint with a success rate of 84.5% for solithromycin and 86.6% for moxifloxacin with a 95% confidence interval for the treatment difference at lower and upper bounds of -7.1 and 2.8, respectively. Treatment emergent adverse events were comparable for the two patient groups with 155 (36.6%) reported for solithromycin and 154 (35.6%) for moxifloxacin. There were no serious adverse events attributed to solithromycin. There were more Grade 4 ALT elevations among patients who received moxifloxacin (1.2%) compared to solithromycin (0.5%). In addition, there were two cases of C. difficile infection, both of which occurred in the moxifloxacin group.

Cempra, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Cempra, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported a net loss of $17.4 million, or $0.41 per basic and diluted share, compared to a net loss of $17.0 million, or $0.51 per basic and diluted share, for the same period in 2014. Revenues were $13,963,000 compared to $3,083,000 a year ago. Loss from operations was $16,804,000 compared to $16,490,000 for the same period last year.

Cempra, Inc. to Report Q1, 2015 Results on Apr 30, 2015

Cempra, Inc. announced that they will report Q1, 2015 results at 5:00 PM, Eastern Standard Time on Apr 30, 2015

Similar Private Companies By Industry

Company Name Region
Pharmacia & Upjohn Company, LLC United States
Advanced Nutritional Technology Inc. United States
BASi Northwest Laboratory, Inc. United States
Pure Nature, LLC United States
Women First Healthcare Inc., Equagesic, Synalgos, and Wygesic Product Lines United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cempra, Inc., please visit www.cempra.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.